This case report describes the occurrence of hyperbilirubinemia as a complication of metastatic melanoma. A 72-year-old male patient was diagnosed with BRAF V600E-mutated melanoma with metastases in the liver, lymph nodes, lungs, pancreas, and stomach. Due to a lack of clinical data and specific guidelines for the treatment of mutated metastatic melanoma patients with hyperbilirubinemia, a conference of specialists debated between initiating treatment or providing supportive care. Ultimately, the patient was started on the combination therapy of dabrafenib and trametinib. This treatment resulted in a significant therapeutic response via normalization of bilirubin levels and an impressive radiological response of metastases just one month post-treatment initiation.
CITATION STYLE
Shalata, W., Steckbeck, R., Polishchuk, I., Cohen, A. Y., Rouvinov, K., Tokar, M., … Yakobson, A. (2023). Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1102330
Mendeley helps you to discover research relevant for your work.